Correction to: Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-blind, randomized, placebo-controlled multi-center clinical trial (Neuropsychopharmacology, (2022), 47, 8, (1574-1581), 10.1038/s41386-022-01266-9)
Chadi G. Abdallah, John D. Roache, Ralitza Gueorguieva, Lynnette A. Averill, Stacey Young-McCaughan, Paulo R. Shiroma, Prerana Purohit, Antoinette Brundige, William Murff, Kyung Heup Ahn, Mohamed A. Sherif, Eric J. Baltutis, Mohini Ranganathan, Deepak D’Souza, Brenda Martini, Steven M. Southwick, Ismene L. Petrakis, Rebecca R. Burson, Kevin B. Guthmiller, Argelio L. López-RocaKarl A. Lautenschlager, John P. McCallin, Matthew B. Hoch, Alexandar Timchenko, Sergio E. Souza, Charles E. Bryant, Jim Mintz, Brett T. Litz, Douglas E Williamson, Terence M. Keane, Alan L Peterson, John H. Krystal
Research output: Contribution to journal › Comment/debate › peer-review
Fingerprint
Dive into the research topics of 'Correction to: Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-blind, randomized, placebo-controlled multi-center clinical trial (Neuropsychopharmacology, (2022), 47, 8, (1574-1581), 10.1038/s41386-022-01266-9)'. Together they form a unique fingerprint.